Guide
Incretin receptor agonists
Built from index records dated 2026-10-09 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works
Incretin receptor agonists is a group of 12 entries in this index, of which this site describes none and holds all 12 back pending review.
Every entry in this group is held back, so this page explains the group and names its members without describing any of their research records.
What this group is
This group holds 12 entries, and every one of them carries a receptor or a pathway named in its records.
Every one of them points at the same place: GLP-1 receptor. A shared target is what holds this group together.
-
Named in the records of 12 of the 12 entries in this group.
-
Named in the records of 4 of the 12 entries in this group.
-
Named in the records of 3 of the 12 entries in this group.
What is held back
12 entries in this group are built and then held back, because publishing them without a qualified reviewer would risk being read as medical guidance. They are: Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Survodutide, Mazdutide, Maridebart cafraglutide, Exenatide, Dulaglutide, Lixisenatide, Orforglipron and GLP-1. This page says nothing about what their records contain. Why entries are held back.
What is not known
- Whether the members of this group have anything in common beyond what the counts above show. A shared receptor is a shared target, not a shared result.
- What any of these entries does in a body. Nothing on this site has been read in full, and no record here has been appraised by anyone qualified to appraise it.
- Anything at all about the held-back entries named above, beyond the fact that they exist and are being withheld.
Read next
Where this comes from
This page reprints no wording from the underlying index. These are the published records that index cites for the existence of this group, listed so the grouping can be checked rather than taken on trust.
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther (2024). pmid:39289339
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ (2024). pmid:38286487
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (2023). pmid:37385280